HSBC Maintains Buy on Regeneron Pharmaceuticals, Lowers Price Target to $880

Benzinga Newsdesk www.benzinga.com Negative 55.6%

Neg 55.6% Neu 0% Pos 0%

HSBC analyst Rajesh Kumar maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and lowers the price target from $990 to $880.